IBM enters June in a striking contradiction: the stock has rallied 31% in a single week and 42% over the past month to close at $329.23, yet short sellers have been quietly and persistently adding to positions at every step of that climb.
The short interest story has turned notably more active. IBM's SI % of Free Float has risen from 2.3% in late April to 3.2% today — a 28% week-on-week increase in shares borrowed. That's not a crowded short by any measure, but the rate of change is unusual. Shorts have added roughly 8 million shares in six weeks while the stock surged from the low $240s. Whatever the thesis is — stretched valuation, AI hype fatigue, post-squeeze unwinding — it has attracted incremental conviction even as the tape moved against it.
The borrow market, however, tells a very different story. With availability running at over 2,250% of current short interest, there are roughly 22 shares available to borrow for every one already lent out. Cost to borrow is a near-frictionless 0.48%, down about 7% on the week. That level of availability rules out any near-term squeeze dynamic — new shorts face no borrow constraint whatsoever. The ORTEX short score of 37.2 reflects this: elevated enough to note, but nowhere near distressed territory.
Options positioning adds another layer of complexity. Call sentiment has dominated recently, with the put/call ratio at 0.70 — a full standard deviation below its 20-day average of 0.77 and close to its 52-week low of 0.62. That's call-heavy positioning. It suggests that the options market, far from hedging against the rally, is leaning into it. The sharp divergence between rising short interest and call-heavy options positioning is the central tension right now: one part of the market is betting the move has legs, another is quietly fading it.
The Street's position is complicated by a stock that has now blown well past most price targets. Barclays initiated coverage on June 1 with an Overweight rating and a $350 target — above the current consensus mean of $290. Wedbush has repeatedly reiterated its Outperform at $320. But the stock is already trading at $329, above every published target except Barclays' fresh initiation. Bulls point to IBM's $10 billion quantum computing commitment, its entrenched Fortune 500 client base, and hybrid cloud positioning. Bears — and the EV/EBITDA of 17x, a P/E near 25.6x, and a price-to-book of 7.5x all support them — argue that the valuation now prices in an optimistic AI and quantum monetisation timeline that remains years away. The analyst recommendation divergence factor scores in the 99th percentile, meaning the gap between bullish and bearish views is wider than almost any stock in the universe.
The last earnings event (April 22) is worth noting here. IBM fell 9.6% on the day and 11.2% over the following five days after that print — a sharp negative reaction that preceded the current rally. The stock has since recovered all of that and then some. The next earnings release is due July 22, which frames the next six weeks as the critical holding period for any position built at current levels.
Peers closed the week more modestly. CTSH gained 6.4% on the week while ACN added 5.2%. IBM's 31% outperformance against both is stark. Whether that gap closes, and in which direction, is the question July 22 will likely answer.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
